Skip to main content
Clinical Trials/NCT07844668
NCT07844668Enrolling By InvitationNot Applicable

Microbiome, Dietary and Quality of Life Analysis of People Living With CVID Treated With or Without Immunoglobulins.

Universitair Ziekenhuis Brussel2 sites in 1 country70 target enrollmentStarted: August 15, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
70
Locations
2
Primary Endpoint
Primary outcomes

Study Overview

Brief Summary

Our research group focusses on finding evidence-based diet strategies to overcome immune dysregulation either due to immune checkpoint inhibitors (ICI) or common variable immunodeficiency (CVID) (Figure 1). CVID is an inborn error of immunity, which is defined, among other factors, by a low level of immunoglobulins, resulting in an increased risk of infections, auto-immune/inflammatory diseases, and cancer.

The gut microbiome (GM) plays a crucial role in maintaining immune homeostasis and modulating the host's innate and adaptive immune responses. Modulation of the GM can be achieved by dietary interventions that have been demonstrated to change the composition of the GM within 2 weeks (Oliver et al., 2021). The intake of more than 30 different plant products (vegetables, fruits, seeds and grains) on a weekly basis is associated with a more diverse microbiome in healthy adults (McDonald et al., 2018). Although direct proof of a link between diet and functioning of the immune system is lacking, it is striking that in a retrospective study, melanoma patients treated with immune checkpoint inhibitors (ICI) had a better overall survival when they consumed enough fibers without taking probiotics (Spencer et al., 2021). Currently, we have included 54 of 60 foreseen patients receiving ICI in an interventional study (FORX-01 (NCT05832606)) at our centre, providing them weekly with 30 different plants to be integrated in their diet (funded by Delhaize and FWO). The aim is to measure if the interventional group develops less immune-related adverse events (= side effects of ICI) by changing their GM.

Similarly, we hypothesize that introducing a fiber-rich diet in patients with CVID will result in a more diverse GM leading to a decrease in autoimmune disorders and infections and as such lead to an improvement of quality of life. To challenge this hypothesis, we plan to organize a similar diet trial, called KNIVES. To prepare this study, we will first perform an observational study to describe the microbiome of people with CVID (DELICIOUS) followed at UZ Brussel.

Study Design

Study Type
Interventional
Allocation
N/A
Intervention Model
Single group
Primary Purpose
Supportive care
Masking
None (open label)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • CVID diagnosis according to ESID criteria
  • 18y or older

Exclusion Criteria

  • start of therapeutic doses of antibiotics < 30 days prior to inclusion
  • start of an immunomodulator < 30 days prior to inclusion Patient excluded for the above reasons will be able to step in the study at a later timepoint (30 days after start of antibiotics of immunomodulators)

Arms & Interventions

CVID participants of Observational cohort

Other

Participants assigned to this arm will follow a high-fiber dietary intervention according to the study protocol. Clinical outcomes, gastrointestinal symptoms, dietary intake, and biological samples will be collected throughout the study to assess the effects of the intervention.

Intervention: Diet (Other)

Outcomes

Primary Outcomes

Primary outcomes

Time Frame: 1 year

To describe the gut microbiome of people living with CVID followed at UZ Brussel. To perform microbiome analysis through metagenomics (depending on availability, pricing, and emerging literature). To analyze one faecal sample of each participant at inclusion and additionally during infectious or autoinflammatory events. To assess microbiome diversity and composition, including: Alpha-diversity. Beta-diversity. Firmicutes/Bacteroidetes ratio (as a proximal marker for dysbiosis). Abundance of specific short-chain fatty acid-producing genera, including: Prevotella. Lactobacillaceae. Bifidobacteriaceae. Lachnospiraceae.

Secondary Outcomes

  • Secondary outcome(1 year)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Identifiers

NCT ID
NCT07844668
Other Study IDs
DELICIOUS

Dates

First Submitted
(9 days ago)
First Posted
(2 days ago)
Primary Completion
(next year)
Study Completion
(next year)
Last Verified
(3 months ago)
Last updated
(2 days ago)

Regulatory & Sharing

FDA Regulated Drug
No
FDA Regulated Device
No
IPD Sharing Plan
No
Has Results
No

Similar Trials